PMDA drug package insert
フルボキサミンマレイン酸塩錠25mg「タカタ」
PMDA Prescription drug · 高田製薬株式会社 · package insert Jun 13, 2024
Key facts
| Brand names | フルボキサミンマレイン酸塩錠25mg「タカタ」, フルボキサミンマレイン酸塩錠50mg「タカタ」, フルボキサミンマレイン酸塩錠75mg「タカタ」 |
|---|---|
| Nonproprietary names | フルボキサミンマレイン酸塩 |
| Companies | 製造販売元／高田製薬株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 選択的セロトニン再取り込み阻害剤（SSRI） |
| Therapeutic category codes | 871179 |
| YJ codes | 1179039F1150, 1179039F2156, 1179039F3152 |
| Approval numbers | 22200AMX00416, 22200AMX00417, 22200AMX00420 |
| Package insert edition | 第3版 |
| Package insert date | Jun 13, 2024 |
| PMDA document key | 400186_1179039F1150_1 |
| PMDA company code | 400186 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- 1–9 Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: